KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Equity Income (2020 - 2023)

Ginkgo Bioworks Holdings filings provide 4 years of Equity Income readings, the most recent being -$1.1 million for Q4 2023.

  • On a quarterly basis, Equity Income fell 111.19% to -$1.1 million in Q4 2023 year-over-year; TTM through Sep 2024 was -$1.1 million, a 113.18% decrease, with the full-year FY2023 number at -$2.6 million, up 93.98% from a year prior.
  • Equity Income hit -$1.1 million in Q4 2023 for Ginkgo Bioworks Holdings, down from -$67000.0 in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $59.9 million in Q4 2021 to a low of -$39.7 million in Q3 2021.
  • Median Equity Income over the past 4 years was -$4.3 million (2021), compared with a mean of -$5.1 million.
  • The widest YoY moves for Equity Income: up 368.11% in 2021, down 16630.38% in 2021.
  • Ginkgo Bioworks Holdings' Equity Income stood at -$22.3 million in 2020, then soared by 368.11% to $59.9 million in 2021, then tumbled by 83.31% to $10.0 million in 2022, then tumbled by 111.19% to -$1.1 million in 2023.
  • The last three reported values for Equity Income were -$1.1 million (Q4 2023), -$67000.0 (Q2 2023), and -$1.4 million (Q1 2023) per Business Quant data.